Form 4: Moderna CFO James Mock Reports Equity Transactions

Moderna's Chief Financial Officer, James M. Mock, reported the vesting of restricted stock units, subsequent tax-related share dispositions, and the grant of new equity awards.

Summary

• James M. Mock, Chief Financial Officer of Moderna, Inc. (MRNA), reported multiple equity transactions.
• On February 27, 2026, Mr. Mock acquired a total of 10,004 shares of common stock (329 + 774 + 9,901) through the vesting of restricted stock units.
• Concurrently, 5,323 shares (160 + 375 + 4,788) were disposed of at a price of $51.71 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Mr. Mock's direct beneficial ownership of common stock was 50,905 shares.
• On March 1, 2026, Mr. Mock was granted a stock option to buy 37,639 shares of common stock at an exercise price of $53.57 per share, with 25% vesting on March 1, 2027, and the remainder vesting in twelve equal quarterly installments thereafter until March 1, 2036.
• Also on March 1, 2026, Mr. Mock was granted 49,569 restricted stock units, with 25% vesting on March 1, 2027, and the remainder vesting in twelve equal quarterly installments thereafter.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting routine executive compensation and continued alignment of management incentives with shareholder interests, without indicating any immediate operational or financial shifts.

Positives

• The CFO received significant new equity awards (stock options and restricted stock units), indicating continued alignment of management's interests with shareholders.
• The vesting of previously granted restricted stock units represents a realization of compensation for the CFO.

Negatives

• A portion of the vested shares was sold to cover tax obligations, which is a common practice but reduces the direct shareholding.

Future Outlook

The filing indicates future vesting schedules for newly granted stock options and restricted stock units, with initial vesting dates in March 2027 and subsequent quarterly installments.

Industry Context

StockSavvy.ai notes that executive equity awards and subsequent tax-related dispositions are standard practices in the biotechnology and pharmaceutical industries, aligning executive incentives with long-term company performance. The grant of new equity awards suggests continued confidence in the executive team's role in Moderna's future strategy.

Comparison to Industry Standards

• The structure of equity compensation, involving restricted stock units and stock options with multi-year vesting schedules, is consistent with compensation practices observed at comparable biotech firms such as BioNTech SE, Pfizer Inc., and Johnson & Johnson.
• These companies also utilize performance-based equity to retain and incentivize key executives.
• The specific vesting schedules (e.g., 25% initial vesting, then quarterly) are common mechanisms to ensure long-term commitment across the industry.

Related Party Transactions

• The reported transactions involve the company's Chief Financial Officer, James M. Mock, acquiring and disposing of company stock, which constitutes related party transactions in the context of executive compensation.

Stakeholder Impact

• Shareholders: The grant of new equity awards to the CFO aligns his financial interests with long-term shareholder value creation. The disposition of shares for tax purposes is a routine event and has a minimal dilutive effect.
• Management: The CFO's compensation package is enhanced through new equity grants, incentivizing continued performance.

Next Steps

• Future vesting of remaining restricted stock units on a quarterly basis.
• Future vesting and exercisability of the newly granted stock options and restricted stock units, starting March 1, 2027, and continuing quarterly thereafter.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including the vesting of equity awards and the grant of new ones, along with tax-related share dispositions. It does not contain information that would fundamentally alter the investment thesis for Moderna. While the continued alignment of executive incentives is a minor positive, the filing itself does not provide new operational or financial data to warrant a change in investment posture. Therefore, a 'hold' recommendation is appropriate as investors should rely on broader company performance and market trends rather than these routine insider transactions.

Keywords

Moderna, MRNA, James Mock, CFO, Form 4, insider trading, equity awards, restricted stock units, stock options, executive compensation, share vesting, tax withholding